Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | MME | P08473 | 1/20 | 0.41 |
| ▸ | CTSB | P07858 | 1/20 | 0.41 |
| ▸ | PPARA | Q07869 | 1/20 | 0.40 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18263742 | 0.92 | HTT (0.48) | HTTSMN1; SMN2FOLH1TSHRSLC1A1 | |
| SCHEMBL11120621 | 0.92 | HTT (0.48) | HTTSMN1; SMN2FOLH1TSHRSLC1A1 | |
| SCHEMBL18263766 | 0.92 | HTT (0.48) | HTTSMN1; SMN2FOLH1TSHRSLC1A1 | |
| SCHEMBL27523288 | 0.86 | SLC1A1 (0.50) | FOLH1TSHRSLC1A1ALDH1A1MME | |
| SCHEMBL22087968 | 0.86 | MMP3 (0.46) | HTTSMN1; SMN2FOLH1TSHRSLC1A1 | |
| SCHEMBL6263485 | 0.83 | MMP3 (0.48) | HTTSMN1; SMN2FOLH1 | |
| SCHEMBL18112961 | 0.83 | HTT (0.46) | HTTSMN1; SMN2FOLH1TSHRALDH1A1 | |
| SCHEMBL7382177 | 0.82 | FOLH1 (0.48) | HTTSMN1; SMN2FOLH1CYP2C19CTSB | |
| SCHEMBL11121387 | 0.80 | TSHR (0.48) | HTTSMN1; SMN2TSHRALDH1A1CYP2C19 | |
| SCHEMBL28425565 | 0.80 | TSHR (0.48) | HTTSMN1; SMN2TSHRALDH1A1CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1355784-A | Mono-and disubstituted 3-propyl-gamma-aminobutyric acids | WARNER LAMBERT CO (US) | 2002-06-26 | — | — | CN | claimed |
| CN-101862317-A | The pregabalin derivant that is used for the treatment of fibromyalgia and other disease | WARNER LAMBERT CO | 2010-10-20 | — | — | CN | disclosed |
| CN-101283995-A | Different pharmaceutical uses alpha2delta ligands | WARNER LAMBERT CO (US) | 2008-10-15 | — | — | CN | disclosed |
| CN-1310872-C | Mono- and disubstituted 3-propyl gamma-aminobutyric acids | WARNER LAMBERT CO (US) | 2007-04-18 | — | — | CN | disclosed |
| CN-1878546-A | Combination comprising an alpha-2 delta ligand and an SSRI and/or SNRI for the treatment of depression and anxiety | WARNER LAMBERT CO (US) | 2006-12-13 | — | — | CN | disclosed |
| CN-1726015-A | Alpha 2 delta ligands for different pharmaceutical uses | WARNER LAMBERT CO (US) | 2006-01-25 | — | — | CN | disclosed |
| CN-1726023-A | Pregabalin derivatives for the treatment of fibromyalgia and other diseases | WARNER LAMBERT CO (US) | 2006-01-25 | — | — | CN | disclosed |
| CN-1678298-A | Use of an alpha2delta ligand such as gabapentin or pregabalin for treating ttention deficit hyperactivity disorder | WARNER LAMBERT CO (US) | 2005-10-05 | — | — | CN | disclosed |
| CN-1660779-A | Mono- and disubstituted 3-propyl gamma-aminobutyric acids | WARNER LAMBERT CO (US) | 2005-08-31 | — | — | CN | disclosed |
| CN-1625393-A | Alpha 2 delta ligands to treat tinnitus | WARNER LAMBERT CO (US) | 2005-06-08 | — | — | CN | disclosed |
| CN-1196671-C | Mono-and disubstituted 3-propyl-gamma-aminobutyric acids | WARNER LAMBERT CO (US) | 2005-04-13 | — | — | CN | disclosed |
| CN-1355784-A | Mono-and disubstituted 3-propyl-gamma-aminobutyric acids | WARNER LAMBERT CO (US) | 2002-06-26 | — | — | CN | disclosed |